Premium
Tocilizumab adverse events and drugs‐related reactions in Rheumatoid Arthritis: a meta‐analysis study
Author(s) -
Espinoza Vallejo Maria Elena,
Manzano Santana Patricia,
Orellana Manzano Silvia,
Orellana Manzano Andrea
Publication year - 2021
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2021.35.s1.05341
Subject(s) - tocilizumab , medicine , rheumatoid arthritis , adverse effect , population , pharmacovigilance , intensive care medicine , environmental health
Rheumatoid Arthritis is a Systemic Autoimmune Disease in which the main character is to cause an inflammation in the synovial membrane that protects and lubricates the joints causing pain, swelling, stiffness, and loss of functions, and progressive destruction in different degrees. For some years now, biological medicines have been used in the treatment of rheumatic diseases. Despite the critical benefits they provide, they carry harmful side effects. This work aims to compare the adverse events reported in the Uppsala VigiAccess database and the scientific literature reviews that describe the adverse events in using the drug Tocilizumab. A systemic review of scientific articles corresponding to the administration and adverse effects of Tocilizumab was carried out, using scientific bases such as Google Scholar, ClinicalKey, PubMed, Scopus, and the comparison of adverse events reported in the VigiAccess database. As a results, the data obtained according to the VigiAccess database indicates that the population between 40 and 64 years of age is the most prone to suffer adverse reactions to Tocilizumab, with a value of 11,756 reported cases; this differs from what is observed in scientific publications, where the age group 65‐74 years was the most prone to adverse reactions, followed by the 45‐64 year group (3,881 and 581 cases, respectively). It is recommended to observe the Reports' Analysis to gather the necessary information to identify the most common adverse events to medications during the treatments with Tocilizumab; developing informative and educational strategies aimed at health personnel and patients for their prevention.